# Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents

> **NCT02075203** · PHASE2 · COMPLETED · sponsor: **Aeras** · enrollment: 989 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **BIOLOGICAL:** AERAS-404
- **DRUG:** Placebo
- **BIOLOGICAL:** Bacillus Calmette-Guérin (BCG)

## Key facts

- **NCT ID:** NCT02075203
- **Lead sponsor:** Aeras
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2017-08-28
- **Final completion:** 2017-10-06
- **Target enrollment:** 989 (ACTUAL)
- **Last updated:** 2019-09-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02075203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02075203, "Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02075203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*